Full Text View
Tabular View
No Study Results Posted
Related Studies
Buprenorphine Detoxification - BBDVI - 19
This study has been completed.
Study NCT00000237   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: August 16, 2005   History of Changes

September 20, 1999
August 16, 2005
May 1997
 
  • Drug use
  • Retention
  • Weeks abstinent
  • Weeks continuous abstinence
  • Overall treatment outcome
  • Opioid dependence and psychiatric status
Same as current
Complete list of historical versions of study NCT00000237 on ClinicalTrials.gov Archive Site
 
 
 
Buprenorphine Detoxification - BBDVI - 19
Buprenorphine Detoxification - BBDVI

The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.

 
Phase II
Interventional
Treatment
Opioid-Related Disorders
Drug: Buprenorphine
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000237
 
NIDA-06969-19, R01-06969-19
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
National Institute on Drug Abuse (NIDA)
May 1997

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP